{"id":"NCT01000727","sponsor":"GlaxoSmithKline","briefTitle":"The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial","officialTitle":"A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12-01","primaryCompletion":"2014-04-01","completion":"2014-04-24","firstPosted":"2009-10-23","resultsPosted":"2017-08-10","lastUpdate":"2017-08-10"},"enrollment":13026,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Coronary Syndrome"],"interventions":[{"type":"DRUG","name":"Darapladib 160 mg","otherNames":["SB-480848"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"OTHER","name":"Standard Therapy","otherNames":[]}],"arms":[{"label":"Darapladib 160 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).","primaryOutcome":{"measure":"Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events During the Time Period for Follow-up (FU) of Cardiovascular (CV) Event","timeFrame":"From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)","effectByArm":[{"arm":"Placebo","deltaMin":910,"sd":null},{"arm":"Darapladib 160 mg","deltaMin":903,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.929"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":18},"locations":{"siteCount":914,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Denmark","France","Germany","Hungary","India","Israel","Italy","Japan","Netherlands","New Zealand","Peru","Philippines","Poland","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["30371283","29018021","28077384","25173516","21982651"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":3011,"n":6465},"commonTop":["Diarrhoea","Non-cardiac chest pain","Hypertension","Angina pectoris","Dizziness"]}}